NDA 203858 · Chiesi
Juxtapid
Lomitapide Mesylate · Oral
NovelOrphanLast checked: Nov 20, 2026Latest source record: Feb 25, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2012
Dec 21, 2012
Approved uses
2
Original approval plus efficacy supplements
Registered trials
16
5 Phase 3, 0 recruiting
FAERS reports
3,782
1,231 serious, 94 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK OF HEPATOTOXICITY JUXTAPID can cause elevations in transaminases. In the adult clinical trial, 10 (34%) of the 29 patients treated with JUXTAPID had at least one elevation in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥3 times the upper limit of normal (ULN). There were no concomitant clinically meaningful elevations of total bilirubin, international normalized ratio (INR), or alkaline phosphatase. In the pediatric clinical trial (5 to 17 years of age), 6 (14%) of the 43 patients experienced elevations in ALT and/or AST ≥ 3 times ULN. No concomitant clinically meaningful elevations in total bilirubin or alkaline phosphatase were observed [see Warnings and Precautions (5.1) ]. JUXTAPID also increases hepatic fat, with or without concomitant increases in transaminases. The median absolute increase in hepatic fat in adult patients was 6% after both 26...
What it is approved for
From the label in effect Mar 30, 2026.
JUXTAPID is indicated as an adjunct to a low-fat diet and exercise and other low density lipoprotein cholesterol (LDL-C) therapies to reduce LDL-C in adults and pediatric patients aged 2 years and older with homozygous familial hypercholesterolemia (HoFH). JUXTAPID is a microsomal triglyceride transfer protein inhibitor indicated as an adjunct to a low-fat diet and exercise and other low-density lipoprotein cholesterol (LDL-C) therapies, to reduce LDL-C in adult and pediatric patients aged 2 years and older with HoFH. ( 1 ).
Mechanism: JUXTAPID directly binds and inhibits microsomal triglyceride transfer protein (MTP), which resides in the lumen of the endoplasmic reticulum, thereby preventing the assembly of apo B-containing lipoproteins in enterocytes and hepatocytes. This inhibits the synthesis of chylomicrons and VLDL. The inhibition of the synthesis of VLDL leads to reduced levels of plasma LDL-C.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 25, 2026 Supplement 27 · Efficacy · priority review OrphanLabelLetter
- Dec 21, 2012 Original approval · Type 1 - New Molecular Entity NovelOrphanOtherLabelReview
7 products under this application
- JUXTAPID · LOMITAPIDE MESYLATE EQ 2MG BASE · CAPSULE, ORAL · Prescription
- JUXTAPID · LOMITAPIDE MESYLATE EQ 40MG BASE · CAPSULE, ORAL · Discontinued
- JUXTAPID · LOMITAPIDE MESYLATE EQ 20MG BASE · CAPSULE, ORAL · Prescription
- JUXTAPID · LOMITAPIDE MESYLATE EQ 5MG BASE · CAPSULE, ORAL · Prescription
- JUXTAPID · LOMITAPIDE MESYLATE EQ 60MG BASE · CAPSULE, ORAL · Discontinued
- JUXTAPID · LOMITAPIDE MESYLATE EQ 30MG BASE · CAPSULE, ORAL · Prescription
- JUXTAPID · LOMITAPIDE MESYLATE EQ 10MG BASE · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Lomitapide" as an intervention, any sponsor and status, largest first.
- Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRSPivotal-lookingCompleted
Aegerion Pharmaceuticals, Inc.Industry
NCT00559962 · 260 participants · Start Oct 2007 · Primary completion Oct 2008
Drug: AEGR-733; placebo and 6 more · For: Hyperlipidemia
Sites: San Diego, California; Santa Rosa, California; Washington D.C., District of Columbia · 15 sites in all
- AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate HypercholesterolemiaPivotal-lookingCompleted
Aegerion Pharmaceuticals, Inc.Industry
NCT00474240 · 157 participants · Start Apr 2007 · Primary completion Oct 2008
Drug: Atorvastatin 20 mg; AEGR-733 5 mg and 4 more · For: Hypercholesterolemia
Sites: Huntsville, Alabama; Jacksonville, Florida; Ocala, Florida · 17 sites in all
Aegerion Pharmaceuticals, Inc.Industry
NCT00359281 · 125 participants · Start Mar 2006 · Primary completion Nov 2007
Drug: atorvastatin; simvastatin and 4 more · For: Healthy
Sites: Philadelphia, Pennsylvania
Aegerion Pharmaceuticals, Inc.Industry
NCT01760187 · 72 participants · Start Nov 7, 2012 · Primary completion Jun 3, 2013
Drug: lomitapide · For: Healthy Volunteer
Sites: Croydon, United Kingdom
Aegerion Pharmaceuticals, Inc.Industry
NCT00405067 · 60 participants · Start May 2006 · Primary completion Jan 2007
Drug: BMS-201038 (AEGR-733); Ezetimibe · For: Hypercholesterolemia
Sites: Princeton, New Jersey
- Efficacy and Safety of Lomitapide in Paediatric Patients With Homozygous Familial Hypercholesterolaemia (HoFH)Pivotal-lookingCompleted
Amryt PharmaIndustry
NCT04681170 · 46 participants · Start Dec 14, 2020 · Primary completion Oct 16, 2022
Drug: Lomitapide · For: Homozygous Familial Hypercholesterolaemia (HoFH)
Sites: Heidelberg, Germany; Cologne, Germany; Hamburg, Germany · 12 sites in all
Aegerion Pharmaceuticals, Inc.Industry
NCT00690443 · 44 participants · Start May 2008 · Primary completion Sep 2008
Drug: Atorvastatin; AEGR-733 · For: Hypercholesterolemia
Sites: Pinellas Park, Florida; Edina, Minnesota; Mogadore, Ohio · 5 sites in all
Aegerion Pharmaceuticals, Inc.Industry
NCT02080468 · 32 participants · Start Feb 19, 2014 · Primary completion Apr 24, 2014
Drug: lomitapide; EE/norgestimate · For: Healthy
Sites: Dallas, Texas
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea1,076
- weight decreased844
- therapy cessation792
- nausea558
- abdominal pain upper287
- abdominal discomfort242
- flatulence242
- vomiting219
- off label use208
- fatigue206
- hepatic enzyme increased188
- drug dose omission184
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2013 | 86 |
| 2014 | 551 |
| 2015 | 1,346 |
| 2016 | 316 |
| 2017 | 327 |
| 2018 | 343 |
| 2019 | 169 |
| 2020 | 193 |
| 2021 | 137 |
| 2022 | 78 |
| 2023 | 76 |
| 2024 | 64 |
| 2025 | 61 |
| 2026 | 35 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Juxtapid (Lomitapide Mesylate)
2024 spending
$7.0M
Beneficiaries
12
117 claims
Per beneficiary
$582,680
$1,968.68 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $10,792,514 |
| 2021 | $9,434,150 |
| 2022 | $8,527,542 |
| 2023 | $8,683,000 |
| 2024 | $6,992,162 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Lomitapide for the treatment of paediatric patients with homozygous familial hypercholesterolaemia (APH-19): results from the efficacy phase of an open-label, multicentre, phase 3 study.
Masana L, Zambon A, Schmitt CP, et al. · Lancet Diabetes Endocrinol 2024 · Multicenter Study, Clinical Trial, Phase III
- Lomitapide modifies high-density lipoprotein function in homozygous familial hypercholesterolaemia.
Hafiane A, Ronca A, Incerti M, et al. · Eur J Med Res 2025 · Clinical Trial, Phase III
- Lomitapide: navigating cardiovascular challenges with innovative therapies.
Munkhsaikhan U, Ait-Aissa K, Sahyoun AM, et al. · Mol Biol Rep 2024 · Systematic Review
- Long-term hepatic safety of lomitapide in homozygous familial hypercholesterolaemia.
Larrey D, D'Erasmo L, O'Brien S, et al. · Liver Int 2023 · Clinical Trial, Phase III, Research Support, Non-U.S. Gov't
- Efficacy and Safety of Lomitapide in Homozygous Familial Hypercholesterolaemia: A Systematic Review.
Wei N, Hu Y, Li S, et al. · Rev Cardiovasc Med 2022 · Systematic Review
- Lomitapide: a review of its use in adults with homozygous familial hypercholesterolemia.
Perry CM · Am J Cardiovasc Drugs 2013 · Clinical Trial, Phase II, Clinical Trial, Phase III
Sponsor: Chiesi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.